Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -95.23% is 56% above its 5-year average of -214.46%, near the high end of its 5-year range (-642.73%–-53.04%).
2.08% below its 12-month average of -93.29%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -147.09%.
EBITDA MARGIN
-95.23%
EBITDA MARGIN AVG TTM
-93.29%
EBITDA MARGIN AVG 3Y
-143.49%
EBITDA MARGIN AVG 5Y
-214.46%
EBITDA MARGIN AVG 10Y
-278.88%
EBITDA MARGIN AVG 15Y
-207.96%
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-2.08%
CURRENT VS 3Y AVG
+33.63%
CURRENT VS 5Y AVG
+55.60%
CURRENT VS 10Y AVG
+65.85%
CURRENT VS 15Y AVG
+54.21%
CURRENT VS 20Y AVG
N/A
Xenetic Biosciences, Inc.
Market Cap
$4.86M
EBITDA Margin
-95.23%
TTM Avg
-93.29%
3Y Avg
-143.49%
5Y Avg
-214.46%
Market Cap
$4.97M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.72M
EBITDA Margin
-1127.44%
TTM Avg
-14514.89%
3Y Avg
-11694.21%
5Y Avg
-11694.21%
Market Cap
$4.71M
EBITDA Margin
-4837.99%
TTM Avg
-4449.42%
3Y Avg
-4104.15%
5Y Avg
-4023.55%
Market Cap
$4.53M
EBITDA Margin
-13851.65%
TTM Avg
-8371.58%
3Y Avg
-4777.88%
5Y Avg
-3394.57%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | $4.86M | -95.23% | -93.29% | -143.49% | -214.46% |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $4.97M | N/A | N/A | N/A | N/A |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.72M | -1127.44% | -14514.89% | -11694.21% | -11694.21% |
| Imunon, Inc. (IMNN)vs › | $4.71M | -4837.99% | -4449.42% | -4104.15% | -4023.55% |
| CalciMedica, Inc. (CALC)vs › | $4.69M | N/A | N/A | N/A | N/A |
| Lunai Bioworks Inc. (LNAI)vs › | $5.12M | N/A | N/A | N/A | N/A |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.55M | N/A | N/A | N/A | N/A |
| PharmaCyte Biotech, Inc. (PMCB)vs › | $4.53M | -13851.65% | -8371.58% | -4777.88% | -3394.57% |
| Alzamend Neuro Inc (ALZN)vs › | $5.21M | N/A | N/A | N/A | N/A |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.21M | -8.85% | 9.13% | 18.32% | 18.32% |
Gross Margin
100.0%
EBITDA Margin
-95.2%
Operating Margin
-95.2%
Net Margin
-75.9%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -147.09% |
| 2026-03-31 | -62.23% |
| 2025-12-31 | -81.30% |
| 2025-09-30 | -53.04% |
| 2025-06-30 | -122.80% |
| 2025-03-31 | -158.85% |
| 2024-12-31 | -169.41% |
| 2024-09-30 | -81.32% |
| 2024-06-30 | -184.11% |
| 2024-03-31 | -248.31% |
| 2023-12-31 | -186.87% |
| 2023-09-30 | -186.37% |
| 2023-06-30 | -183.61% |
| 2023-03-31 | -148.93% |
| 2022-12-31 | -317.29% |
| 2022-09-30 | -202.74% |
| 2022-06-30 | -642.73% |
| 2022-03-31 | -413.95% |
| 2021-12-31 | -560.65% |
| 2021-09-30 | -391.38% |
| 2021-06-30 | -389.04% |
| 2021-03-31 | -711.59% |
| 2020-12-31 | -800.87% |
| 2020-09-30 | -9055.26% |
| 2020-06-30 | -863.70% |
| 2020-03-31 | -2155.75% |
| 2019-12-31 | -7191.86% |
| 2017-12-31 | 59.14% |
| 2017-09-30 | -2629.62% |
| 2016-12-31 | -1.84% |
| 2013-12-31 | -2696.36% |
| 2013-08-31 | 492.40% |
| 2013-05-31 | -12.73% |
| 2013-02-28 | 72.35% |
| 2012-11-30 | -18.11% |
| 2012-08-31 | -130.77% |
| 2012-05-31 | -83.21% |
| 2012-02-29 | -57.70% |
| 2011-11-30 | -82.01% |
